Companies › Endo USA Inc., a Keenova Therapeutics Company
1 active drug program in 6 registered trials: 5 Phase 4, 1 Phase 3; Genitourinary, Other; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Collagenase Clostridium Histolyticum (KN3835) Collagen hydrolytic enzyme | COL1A2, COL1A1, COL2A1, COL3A1, COL4A1 | Phase 3 | Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger … | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05777031 | Collagenase Clostridium Histolyticum (KN3835) | Phase 4 | Peyronie Disease | Genitourinary | Jan 2027 |
| NCT04786106 | Collagenase Clostridium Histolyticum (KN3835) | Phase 4 | Peyronie's Disease | Genitourinary | Feb 2027 |
| NCT03406338 | Collagenase Clostridium Histolyticum (KN3835) | Phase 4 | Dupuytren Disease of Finger | Other | Sep 2027 |
| NCT07759362 | Collagenase Clostridium Histolyticum (KN3835) | Phase 3 | Flexible Hammertoe | Other | Dec 2027 |
| NCT06649539 | Collagenase Clostridium Histolyticum (KN3835) | Phase 4 | Peyronie Disease | Genitourinary | Oct 2029 |
| NCT03192020 | Collagenase Clostridium Histolyticum (KN3835) | Phase 4 | Dupuytren Contracture | Other | May 2031 |
–
Hansa Biopharma Heron Therapeutics CellTherX Innovacell CUTISS
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.